Guideline-recommended medications: variation across medicare advantage plans and associated mortality.
New Bedford, United States. In J Manag Care Pharm, 31 Mar 2013
We linked data from the Medicare Health Outcomes (HOS) Survey cohort 9 (April 2006-May 2008) with the Medicare Part D prescription benefit files (January 1, 2006-December 31, 2007) to examine variation in treatment across MA plans and its association with differences in observed (O)/expected (E) mortality ratio for 5 high-volume chronic conditions: diabetes, coronary artery disease (CAD), congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD)/asthma, and depression.
The Combination of Sorafenib and Everolimus abrogates mTORC-1 and mTORC2 up-regulation in preclinical models of Osteosarcoma.
Torino, Italy. In Clin Cancer Res, 22 Mar 2013
Cell viability, colony growth, and cell migration were evaluated in different osteosarcoma cell lines (MNNG-HOS, HOS, KHOS/NP, MG63, U-2OS, SJSA-1, SAOS-2) after scalar dose treatment with sorafenib (10-0.625 muM), rapamycin-analog everolimus (100-6.25 nM), and combinations of the two.
Alternative splicing of T-box transcription factor genes.
Birmingham, United States. In Biochem Biophys Res Commun, 2011
Currently, TBX3, TBX5, and TBX20 are TBX genes defined to have multiple protein isoforms created by alternative splicing and characterized by expression and functional studies.
Genome-wide association study of PR interval.
München, Germany. In Nat Genet, 2010
Six of the loci were near cardiac developmental genes, including CAV1-CAV2, NKX2-5 (CSX1), SOX5, WNT11, MEIS1, and TBX5-TBX3, providing pathophysiologically interesting candidate genes.
Divergent transcriptional activities determine limb identity.
Montréal, Canada. In Nat Commun, 2009
Data show that Tbx4 and Tbx5 harbour conserved and divergent transcriptional regulatory domains that account for their roles in limb development. In particular, both factors share an activator domain and the ability to stimulate limb growth